Topic: point-of-care diagnostics
MeMed raised $70 million for its immune system diagnostic for distinguishing between bacterial and viral infections, to reduce antibiotic misuse.
Diagnostic maker Echosens is teaming up with a consortium of health systems to develop a real-world evidence model to help standardize care for NASH.
Diassess was awarded a federal contract worth up to $21.9 million to develop an at-home flu diagnostic test.
Sight Diagnostics received a CE mark for its point-of-care blood diagnostic that uses AI to optically read samples and provide complete blood counts.
Biodesix acquired Integrated Diagnostics and its XL2 lung cancer blood test, which aims to help screen patients that can avoid nodule biopsies.
The $4.4 million award sets Talis up to work on a molecular diagnostic capable of detecting the bacteria in patient samples within 20 minutes.
Mammoth Biosciences is developing a CRISPR-based platform to detect any biomarker containing DNA or RNA.
The deal will give Axcel a portfolio of in vitro diagnostics and point-of-care testing systems that generated sales of $66 million last year.
Biosensorix's new collaboration will give it access to an electrochemical lateral flow immunosensor.
Qiagen will gain control of a pipeline of assay panels designed to diagnose infections affecting the respiratory and gastrointestinal systems.